The Alliance for Regenerative Medicine Releases 2017 Annual Data Report, Highlighting Sector Trends and Metrics

WASHINGTON, D.C., March 05, 2018 -- The Alliance for Regenerative Medicine (ARM) today announced the release of its 2017 Annual Data Report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector.

Using data provided by ARM’s data partner Informa, curated and further analyzed by ARM’s staff, the report details industry-specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. Key features of the report include total financings for the sector, partnerships and other deals, clinical trial information, major clinical data events, current legislative and regulatory priorities, and ARM’s 2017 highlights and strategic priorities for the year ahead.

Key findings from the 2017 annual report include:

• Globally, companies active in gene and cell therapies and other regenerative medicines raised more than $7.5 billion in 2017. The report also includes data broken out by technology and financing type.
• There were 946 clinical trials underway worldwide by year-end 2017, an 18% increase over the previous year. The report includes figures on clinical trials by phase, technology type, and indication. 
• Areas of strategic focus for ARM in 2018, including promoting clear, predictable, and efficient regulatory frameworks; securing favorable access and reimbursement for regenerative medicine and advanced therapy products; reducing the standards, technical and regulatory barriers to scale up; and more. 

“These groundbreaking product approvals and continued clinical momentum in 2017 fostered growing investor and overall public interest regarding the truly transformative potential of these therapies,” noted Janet Lambert in her “Letter from the CEO” included in the report. “This increased attention and anticipation has heightened the importance of ARM’s role as the leading advocate for legislative, regulatory, and financial support for the development of regenerative medicine therapies.”

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events. 

The report is available to download online here. Past reports, issued quarterly and annually, are available here.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors, and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Lyndsey Scull
202-213-7086
[email protected]